Site icon OncologyTube

Update on PI3K inhibitors for CLL: Idelalisib, copanlisib, duvelisib, and umbralisib

Earn CME: https://naccme.com/program/7314

In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application of Emerging Agents and Combinations in Practice symposium, Dr. Jennifer R. Brown provides an update on PI3K inhibitors for CLL.

© 2018 Imedex, an HMP Company

Advertisement
Exit mobile version